<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04465838</url>
  </required_header>
  <id_info>
    <org_study_id>2020-354</org_study_id>
    <nct_id>NCT04465838</nct_id>
  </id_info>
  <brief_title>Chinese Psoriasis Real World Evidence Research</brief_title>
  <official_title>A Real World Evidence Study in Chinese Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <brief_summary>
    <textblock>
      This research is a multicenter,observational study under real world settings in patients&#xD;
      diagnosed as psoriasis by dermatologist in the clinic. As patient's choice of medication&#xD;
      should be fully respected, all the patients can choose the treatments they prefer, like&#xD;
      phototherapy, traditional systemic therapy or biologics. And the study was conducted to&#xD;
      compare the effectiveness among different choices of medication in Chinese psoriasis&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic, recurrent inflammatory disease which is caused by heredity,&#xD;
      environment and other factors. The typical clinical manifestation are erythematosquamous&#xD;
      lesions, and the disease can progress to involve several organs. In view of its complex&#xD;
      pathogenesis, there exists various of treatment of psoriasis like traditional systemic drugs&#xD;
      and biologics.&#xD;
&#xD;
      This study is an observational, multi-centre study based on real-world evidence. Inclusion&#xD;
      criteria is the patients who visit the clinic diagnosed psoriasis by the dermatologist. There&#xD;
      existed no exclusion criteria. Information were most collected by a phone application called&#xD;
      &quot;Psoriasis New World&quot;.&#xD;
&#xD;
      Primary outcome measure is the percentage of patients who achieved a PASI reduction of 100%&#xD;
      (PASI 100). And Psoriasis Area and Severity Index includes scores of erythema, infiltration&#xD;
      and desquamation, weighted by area of involvement in each regions (head and neck, upper&#xD;
      extremities, trunk, lower extremities), with higher PASI scores indicating worse condition.&#xD;
      Also, static Physician Global Assessment (sPGA), static Investigator Global Assessment&#xD;
      (sIGA), Body surface area (BSA) and Dermatology Life Quality Index (DLQI) are measured to&#xD;
      assess the severity of psoriasis and the change of the disease condition. It is important to&#xD;
      monitor all the Adverse Events (AEs) over the whole study. In addition, the laboratory&#xD;
      examinations of patients such as liver function are also collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who achieved a PASI reduction of 100% (PASI 100)</measure>
    <time_frame>6 months</time_frame>
    <description>Psoriasis Area and Severity Index includes scores of erythema, infiltration and desquamation, weighted by area of involvement in each regions (head and neck, upper extremities, trunk, lower extremities), with higher PASI scores indicating worse condition. The percentage of patients who achieved a PASI reduction of 100% (PASI 100) will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who achieved a PASI reduction of 100% (PASI 100)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>PASI100 represents complete clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who achieved a PASI reduction of 75% (PASI 75)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>PASI75 response is the percentage of participants who achieved at least a 75% reduction from baseline in PASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who achieved a PASI reduction of 50% (PASI 50)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>PASI50 response is the percentage of participants who achieved at least a 50% reduction from baseline in PASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>static Physician Global Assessment (sPGA) = 0</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>static Physician Global Assessment (sPGA) is an assessment of severity of psoriasis on 5-point scale ranging from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>static Investigator Global Assessment (sIGA) = 0</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>static Investigator Global Assessment (sIGA) is an assessment of severity of psoriasis on 5-point scale ranging from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body surface area (BSA)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The percentage of BSA represents the area of involvement, which can be estimated by the entire palm of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) =0</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is a questionnaire used to measure the impact of a skin disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Visual Analog Scale (VAS) is used to measure lesion pruritus from 0 to 10. The higher score is, the greater discomfortableness participant has.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <description>This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NIS</intervention_name>
    <description>This is a non-interventional study (NIS).</description>
    <arm_group_label>Psoriasis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients diagnosed as psoriasis by dermatologist in clinic were under treatment or&#xD;
        willing to be treated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all the patients diagnosed as psoriasis by dermatologist in clinic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiao-yong Man, MD</last_name>
    <phone>13600516219</phone>
    <email>manxy@zju.edu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Yong Man, MD</last_name>
      <phone>13600516219</phone>
      <email>manxy@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Xu</last_name>
      <phone>15801449886</phone>
      <email>zhexu_cmu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai-jun Chen</last_name>
      <phone>13062377863</phone>
      <email>1360999716@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fujian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Ji</last_name>
      <phone>13075959049</phone>
      <email>surpassing_ji@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Lanzhou Military Region</name>
      <address>
        <city>Gansu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-feng He</last_name>
      <phone>13919914800</phone>
      <email>derma_hcf@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang-chun Wang</last_name>
      <phone>13926496797</phone>
      <email>wliangch@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Peoples' Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Guangxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Xie</last_name>
      <phone>15277094610</phone>
      <email>xz19723@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guizhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong-guang Lu</last_name>
      <phone>13984120866</phone>
      <email>hongguanglu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Hainan Province</name>
      <address>
        <city>Hainan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shi Gong</last_name>
      <phone>13976006125</phone>
      <email>gsxyh1218@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Hebei Medical University</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo-qiang Zhang</last_name>
      <phone>18531117085</phone>
      <email>zgq810328@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Harbin Medical Unviersity</name>
      <address>
        <city>Heilongjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing-xue Bai</last_name>
      <phone>15114517408</phone>
      <email>bxuebdd@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Peoples' Hospital</name>
      <address>
        <city>Henan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Li, MD</last_name>
      <phone>13525585301</phone>
      <email>623108070@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianwen Han</last_name>
      <phone>15047838652</phone>
      <email>hanjianwen1981@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Hubei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Tao</last_name>
      <phone>13986278399</phone>
      <email>tjhappy@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Su</last_name>
      <phone>15116408921</phone>
      <email>sujuanderm@csu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ou-gen Liu</last_name>
      <phone>13576296646</phone>
      <email>13576296646@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yanbian University Hospital</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian-hua Zhu</last_name>
      <phone>15526770355</phone>
      <email>zlh0228@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Dermatology, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Yang</last_name>
      <phone>13661267877</phone>
      <email>dryongyang@bjmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xining First Hospital</name>
      <address>
        <city>Qinghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-mei Huang</last_name>
      <phone>13997291656</phone>
      <email>mawenyu730126@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital for Skin Diseases</name>
      <address>
        <city>Shandong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Liu</last_name>
      <phone>15866796024</phone>
      <email>hongyue2519@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Dermatology Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuling Shi, MD</last_name>
      <phone>13816213884</phone>
      <email>shiyuling1973@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiyuan Central Hospital</name>
      <address>
        <city>Shanxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Shanxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song-mei Geng</last_name>
      <phone>13060423612</phone>
      <email>gsm312@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wu</last_name>
      <phone>15840213656</phone>
      <email>jlwuyan@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Zhu</last_name>
      <phone>13983174426</phone>
      <email>zhshencq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang-jun Kong</last_name>
      <phone>18587535831</phone>
      <email>xiangjunkong00@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, School of Medicine, Shihezi University</name>
      <address>
        <city>Xinjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Zeng</last_name>
      <phone>13899518298</phone>
      <email>zengjia0993@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin-hong Ge</last_name>
      <phone>13895011119</phone>
      <email>gexinhong.0101@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Second Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Yunnan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Guo</last_name>
      <phone>13769111959</phone>
      <email>gunyun256318@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>August 23, 2022</last_update_submitted>
  <last_update_submitted_qc>August 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Xiaoyong Man</investigator_full_name>
    <investigator_title>Principal Investigator, Head of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04465838
org study id: 2020-354
nct id: NCT04465838
lead sponsor: 
This research is a multicenter,observational study under real world settings in patients
      diagnosed as psoriasis by dermatologist in the clinic. As patient's choice of medication
      should be fully respected, all the patients can choose the treatments they prefer, like
      phototherapy, traditional systemic therapy or biologics. And the study was conducted to
      compare the effectiveness among different choices of medication in Chinese psoriasis
      patients.
Psoriasis is a chronic, recurrent inflammatory disease which is caused by heredity,
      environment and other factors. The typical clinical manifestation are erythematosquamous
      lesions, and the disease can progress to involve several organs. In view of its complex
      pathogenesis, there exists various of treatment of psoriasis like traditional systemic drugs
      and biologics.

      This study is an observational, multi-centre study based on real-world evidence. Inclusion
      criteria is the patients who visit the clinic diagnosed psoriasis by the dermatologist. There
      existed no exclusion criteria. Information were most collected by a phone application called
      "Psoriasis New World".

      Primary outcome measure is the percentage of patients who achieved a PASI reduction of 100%
      (PASI 100). And Psoriasis Area and Severity Index includes scores of erythema, infiltration
      and desquamation, weighted by area of involvement in each regions (head and neck, upper
      extremities, trunk, lower extremities), with higher PASI scores indicating worse condition.
      Also, static Physician Global Assessment (sPGA), static Investigator Global Assessment
      (sIGA), Body surface area (BSA) and Dermatology Life Quality Index (DLQI) are measured to
      assess the severity of psoriasis and the change of the disease condition. It is important to
      monitor all the Adverse Events (AEs) over the whole study. In addition, the laboratory
      examinations of patients such as liver function are also collected.
observational model: Other
time perspective: Prospective
measure: The percentage of patients who achieved a PASI reduction of 100% (PASI 100)
time frame: 6 months
description: Psoriasis Area and Severity Index includes scores of erythema, infiltration and desquamation, weighted by area of involvement in each regions (head and neck, upper extremities, trunk, lower extremities), with higher PASI scores indicating worse condition. The percentage of patients who achieved a PASI reduction of 100% (PASI 100) will be measured.
measure: The percentage of patients who achieved a PASI reduction of 100% (PASI 100)
time frame: 6 months and 12 months
description: PASI100 represents complete clearance.
measure: The percentage of patients who achieved a PASI reduction of 75% (PASI 75)
time frame: 6 months and 12 months
description: PASI75 response is the percentage of participants who achieved at least a 75% reduction from baseline in PASI score.
measure: The percentage of patients who achieved a PASI reduction of 50% (PASI 50)
time frame: 6 months and 12 months
description: PASI50 response is the percentage of participants who achieved at least a 50% reduction from baseline in PASI score.
measure: static Physician Global Assessment (sPGA) = 0
time frame: 6 months and 12 months
description: static Physician Global Assessment (sPGA) is an assessment of severity of psoriasis on 5-point scale ranging from 0 to 4.
measure: static Investigator Global Assessment (sIGA) = 0
time frame: 6 months and 12 months
description: static Investigator Global Assessment (sIGA) is an assessment of severity of psoriasis on 5-point scale ranging from 0 to 4.
measure: Body surface area (BSA)
time frame: 6 months and 12 months
description: The percentage of BSA represents the area of involvement, which can be estimated by the entire palm of the patient.
measure: Dermatology Life Quality Index (DLQI) =0
time frame: 6 months and 12 months
description: The Dermatology Life Quality Index (DLQI) is a questionnaire used to measure the impact of a skin disease.
measure: Adverse Events (AEs)
time frame: Up to 12 months
description: Number of patients with adverse events
measure: Visual Analog Scale (VAS)
time frame: 6 months and 12 months
description: Visual Analog Scale (VAS) is used to measure lesion pruritus from 0 to 10. The higher score is, the greater discomfortableness participant has.
arm group label: Psoriasis
description: This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
intervention type: Other
intervention name: NIS
description: This is a non-interventional study (NIS).
arm group label: Psoriasis
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: N/A
maximum age: N/A
healthy volunteers: No
last name: Xiao-yong Man, MD
phone: 13600516219
email: manxy@zju.edu.com
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Enrolling by invitation
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: China
responsible party type: Principal Investigator
investigator affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
investigator full name: Xiaoyong Man
investigator title: Principal Investigator, Head of Dermatology
mesh term: Psoriasis
sharing ipd: Undecided